Futureproofing [18F]Fludeoxyglucose manufacture at an Academic Medical Center

Sowa, Alexandra; Jackson, Isaac M.; Desmond, Timothy J.; Alicea, Jeremiah; Mufarreh, Anthony; Pham, Jonathan; Stauff, Jenelle; Winton, Wade; Fawaz, Maria V.; Henderson, Bradford D.; Hockley, Brian G.; Rogers, Virginia; Koeppe, Robert A.; Scott, Peter

doi:10.1186/s41181-018-0048-x

Cited by 10 publications

(13 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent PET tracers are promising for the application of PET in the initial evaluation of several oncologic diseases [53,54]. Since automated synthesis systems have increased the reliability, reproducibility and safety of radiopharmaceutical productions [55][56][57], the absence of PET services in Nigeria is largely due to the high cost of investment. In the southern hemisphere of Africa, the availability of PET is limited to South Africa and, recently, Kenya.…”

Section: Discussionmentioning

confidence: 99%

Underutilisation of nuclear medicine scans at a regional hospital in Nigeria: need for implementation research

Orunmuyi¹,

Lawal²,

Omofuma³

et al. 2020

ecancer

View full text Add to dashboard Cite

Background: Nuclear medicine needs better integration into the Nigerian health system. To understand the relevant public health initiatives that will be required, this study assessed the pattern of nuclear medicine imaging services at the first nuclear medicine centre in Nigeria from January 2010 to December 2018. Methods: The data of consecutive nuclear medicine (NM) scans performed between 1st January 2010 and 31st December 2018 at the NM department in a tertiary hospital in Nigeria were extracted from patient records and analysed using SAS version 9.4 (SAS Institute, Cary, NC). The National Cancer Institute's Joinpoint software and QCIS (QGIS project) were used to estimate imaging trends and geographical spread of patients. Results: An average of 486 scans per year was performed during the study period. Patients travelled from 32 of Nigeria's 36 states, and the majority (65%) travelled more than 100 km to obtain NM scans. Bone scans accounted for 88.1% of the studies. The remainder were renal scintigraphy (7.3%), thyroid scans (2.5%), whole-body iodine scans (1.7%) and others (0.4%). Conclusions: NM in Nigeria appears underutilised. Furthermore, the studies to characterise the access gaps and implementation needs will contribute to the design of practical strategies to strengthen NM services in Nigeria.

show abstract

Section: Discussionmentioning

confidence: 99%

Underutilisation of nuclear medicine scans at a regional hospital in Nigeria: need for implementation research

Orunmuyi¹,

Lawal²,

Omofuma³

et al. 2020

ecancer

View full text Add to dashboard Cite

show abstract

“…In the studies by Jordan [19] and Teichmann [20], the temporal separation technique was used to suppress the stem effect, but it is not applicable for internal radiation therapy where a time decaying radioactive source is used. Kertzscher and Beddar [22] tested a ruby-based bre optic detector for IVD during high dose rate (HDR) brachytherapy.…”

Section: Introductionmentioning

confidence: 99%

“…The background bre technique is not suitable for in vivo applications as it makes the FOD system bulky. Kertzscher and Beddar [22] concluded by simulations that the stem signal suppression would be better by narrowing the bandpass wavelength region of the bandpass lter to ≤ 20 nm when the optical ltering technique is used. Using a scintillator such as a ruby which has a narrow RL main emission peak at 694 nm with a narrow bandpass lter will effectively suppress the stem effect, making the FOD technique suitable for IVD during internal radiation therapy…”

Section: Introductionmentioning

confidence: 99%

Real-time in vivo dose measurement using ruby-based fibre optic dosimetry during internal radiation therapy

Birajdar

Zhang

Santos

et al. 2022

Preprint

View full text Add to dashboard Cite

In vivo dosimetry (IVD) in a commonly used liver cancer treatment of selective internal radiation therapy (SIRT) has been done based on the post-treatment image-based dosimetry approach. Real-time IVD is necessary to verify the dose delivery and detect errors during the treatment for better patient outcomes. This study aims to develop a fibre optic dosimeter (FOD) for in vivo real-time dose rate measurement during internal beta radiation therapy, e.g., SIRT. A ruby fibre optic probe was prepared and studied the radioluminescence (RL) characteristics, including its major challenge of stem effect arising from Cherenkov radiation and luminescence from the irradiated fibre. The stem signal was suppressed adequately using the stem removal technique of optical filtering, and only 2.3 ± 1. % stem signal was contributed to the measured RL signal. A linear dose rate response was observed during the exposure of the ruby probe to varying dose rates using a 6 MeV electron beam and a positron-emitting radionuclide fluorine-18. The ruby exhibited a temporally non-constant RL signal, which increased the RL signal by 0.84 ± 0.29 counts / sec2 during the irradiation of the maximum dose rate used in this study of 9 Gy / min for 2 minutes. The ability of ruby FOD to measure the absolute dose rate with sufficient stem effect suppression and the linear RL dose rate response indicates its suitability for real-time IVD during internal beta radiation therapy. Future work will investigate the time-dependent RL characteristic of ruby and validate post-treatment image-based dosimetry using ruby-based FOD.

show abstract

“…Since the complex formation at the optimal pH is robust and can be achieved quantitatively within minutes, this labelling approach gained broad application both in research and routine production [ 11 , 12 ]. Standard labelling procedures with 18 F, in contrast, are more complex when covalent C-F bonds are aimed at, as in the labelling process of [ 18 F]fluorodeoxyglucose ([ 18 F]FDG) [ 13 , 14 ]. Over the last ten years, attempts were made to combine the ease of labelling via complexes with the favorable nuclide properties of 18 F (t 1/2 = 109.7 min, ∼97% β + emission, low 0.635 MeV β + energy) [ 15 , 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Labelling via [Al18F]2+ Using Precomplexed Al-NODA Moieties

et al. 2021

View full text Add to dashboard Cite

Over the past 20 years, 68Ga-labelled radiopharmaceuticals have become an important part in clinical routine. However, the worldwide supply with 68Ge/68Ga generators is limited as well as the number of patient doses per batch of 68Ga radiopharmaceutical. In the recent years, a new technique appeared, making use of the ease of aqueous labelling via chelators as with 68Ga but using 18F instead. This technique takes advantage of the strong coordinative bond between aluminium and fluoride, realized in the aqueous cation [Al18F]2+. Most applications to date make use of one-pot syntheses with free Al(III) ions in the system. In contrast, we investigated the labelling approach split into two steps: generating the Al-bearing precursor in pure form and using this Al compound as a precursor in the labelling step with aqueous [18F]fluoride. Hence, no free Al3+ ions are present in the labelling step. We investigated the impact of parameters: temperature, pH, addition of organic solvent, and reaction time using the model chelator NH2-MPAA-NODA. With optimized parameters we could stably achieve a 80% radiochemical yield exerting a 30-min reaction time at 100 °C. This technique has the potential to become an important approach in radiopharmaceutical syntheses.

show abstract

Futureproofing [18F]Fludeoxyglucose manufacture at an Academic Medical Center

Cited by 10 publications

References 4 publications

Underutilisation of nuclear medicine scans at a regional hospital in Nigeria: need for implementation research

Underutilisation of nuclear medicine scans at a regional hospital in Nigeria: need for implementation research

Real-time in vivo dose measurement using ruby-based fibre optic dosimetry during internal radiation therapy

Labelling via [Al18F]2+ Using Precomplexed Al-NODA Moieties

Contact Info

Product

Resources

About